Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05796089

Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy — CHEST RT  

Extensive-Stage Small-Cell Lung Cancer Clinical Trial

Official title:
A Phase II Study of Platinum and Etoposide Chemotherapy, Durvalumab With Thoracic Radiotherapy in the First Line Treatment of Patients With Extensive-stage Small-cell Lung Cancer

Clinical Trial Summary

This is a prospective, multi-centre, single arm, phase 2, open label clinical trial of patients with untreated extensive-stage small-cell lung cancer (ES-SCLC) suitable for first-line platinum-based chemotherapy. The aim of the trial is to assess safety, feasibility and describe efficacy of the addition of concurrent thoracic radiotherapy to usual treatment of chemotherapy and immunotherapy (durvalumab) in patients with ES-SCLC.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05796089
Study type Interventional
Source Trans Tasman Radiation Oncology Group
Contact Bridget Rooney
Phone +61 2 40143911
Email CHESTRT@trog.com.au
Status Recruiting
Phase Phase 2
Start date January 1, 2022
Completion date February 28, 2028
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04985851 - To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS. N/A
Completed NCT01987232 - Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive Stage Small-cell Lung Cancer Phase 1/Phase 2
Recruiting NCT06223711 - Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC Phase 2
Active, not recruiting NCT05002868 - Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors Phase 1
Recruiting NCT04790253 - PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study) N/A
Recruiting NCT05572476 - Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer Phase 2
Recruiting NCT05874401 - Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan Phase 4
Not yet recruiting NCT06008353 - A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in Brazil
Recruiting NCT04947774 - Prophylactic Cranial Irradiation in Extensive-stage Small Cell Lung Cancer
Completed NCT04902885 - Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Extensive-Stage Small Cell Lung Cancer Patients Receiving Carboplatin Combined With Etoposide or Topotecan Phase 3
Recruiting NCT05280470 - Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Phase 2
Recruiting NCT05765825 - Study of Low-Dose Radiotherapy Concurrent Cisplatin/Carboplatin Plus Etoposide With Serplulimab for Patients With ES-SCLC Phase 2
Recruiting NCT05761977 - Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung Cancer
Active, not recruiting NCT05092412 - Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC Phase 2
Not yet recruiting NCT06306560 - A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC. Phase 2
Recruiting NCT04894591 - To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)
Not yet recruiting NCT06211036 - Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab Phase 3
Completed NCT04878016 - A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLC Phase 3
Recruiting NCT04675697 - Anlotinib Plus Platinum-etoposide in First-line of Extensive-stage Small-cell Lung Cancer Phase 2
Recruiting NCT05403723 - Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC Phase 1